Spigel DR, Chaft JE, Gettinger SN et al. Clinical activity a nd safety from a Phase II study OSE2101 Protocol OSE2101C301 Confidential Version n°6.0 Page 87 of 101 02 February 2022 (FIR) of MPDL3280 (anti -PDL1) in PD -L1-selected patients with non -small -cell lung cancer. J Clin Oncol 2015; 33 (suppl; abstract 8028) 76. Spira AI, Park K, Mazières J et al. Efficacy, safety and predictive biomarkers results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2/3L NSCLC (POLAR). J Clin Oncol 2015; 33 (suppl; abstr 8010) 77.